

# Apple Health PDL Drug Class Motions

# Musculoskeletal Therapy Agents : Fibrodysplasia Agents

---

- ▶ **Motion:** I move that all products in the Musculoskeletal Therapy Agents: Fibrodysplasia Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Weiland**
- ▶ **2<sup>nd</sup>: Taylor**

# Antihypertensives

---

- ▶ Direct Renin Inhibitor Combinations
- ▶ Direct Renin Inhibitors
- ▶ Neprilysin Inhib (ARNI)-Angiotensin II Recept Antag Combinations

# Antihypertensives

---

**Motion:** I move that all products in the drug classes listed on slide 3 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Taylor**
- ▶ **2<sup>nd</sup>: Beste**

# Endocrine and Metabolic Agents

---

- ▶ Insulin-Like Growth Factors
- ▶ Natriuretic Peptides

# Endocrine and Metabolic Agents

---

**Motion:** I move that all products in the drug classes listed on slide 5 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Hudson**

# AHDPL Classes

---

## ▶ Analgesics

- ▶ Opioid Agonists - Long Acting

## ▶ Antiemetics / Antivertigo Agents

- ▶ 5-HT<sub>3</sub> Receptor Antagonists
- ▶ Other
- ▶ Substance P/Neurokinin 1 (NK1) Receptor Antagonists
- ▶ Substance P/Neurokinin 1 Receptor Antagonist Combinations

## ▶ Antivirals

- ▶ Hepatitis C Agents - Direct Acting Antivirals
- ▶ Hepatitis C Agents - Misc

# AHDPL Classes

---

- ▶ Contraceptives
  - ▶ Non-Hormonal - Vaginal
- ▶ Dermatologics
  - ▶ Gene Therapy
- ▶ Endocrine and Metabolic Agents
  - ▶ Adrenal Steroid Inhibitors
  - ▶ Androgens – Testosterone
  - ▶ Calcimimetic Agents – Oral
  - ▶ Cortisol Synthesis Inhibitors



# AHDPL Classes

---

- ▶ Endocrine and Metabolic Agents (Cont.)
  - ▶ Hereditary Tyrosinemia Type 1 (HT-1) Agents – Oral
  - ▶ Homocystinuria Agents – Oral
  - ▶ Hyperammonemia Agents – Oral
  - ▶ Mineralocorticoid Receptor Antagonists
  - ▶ Molybdenum Cofactor Deficiency (MOCD) Agents
  - ▶ Pituitary Suppressant Combinations
- ▶ Gastrointestinal Agents
  - ▶ Live Fecal Microbiota

# AHDPL Classes

---

## ▶ Hematological Agents

- ▶ Anti-Von Willebrand Factor Agents

## ▶ Immunosuppressive Agents

- ▶ Rock Inhibitors

## ▶ Migraine Agents

- ▶ Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists
- ▶ Selective Serotonin Agonists 5-HT(1)

## ▶ Ophthalmic Agents

- ▶ Alpha Adrenergic Agonists

# AHDPL Classes

---

- ▶ Pulmonary Hypertension Agents
  - ▶ Endothelin Receptor Antagonists
  - ▶ Phosphodiesterase Inhibitors (PDEI)
  - ▶ Prostacyclin Receptor Agonists
  - ▶ Prostaglandin Vasodilators
  - ▶ SGC Stimulator

# AHDPL Classes

---

**Motion:** I move that all products in the drug classes listed on slides 7, 8, 9, 10 and 11 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Taylor**
- ▶ **2<sup>nd</sup>: Beste**